Studie účinnosti a bezpečnosti Tisagenlecleucelu u brazilských pacientů s akutní lymfoblastickou leukémií nebo difuzním velkobuněčným B-lymfomem
Účinnost a bezpečnost terapie Tisagenlecleucelem u brazilských pacientů s akutní lymfoblastickou leukémií nebo difuzním velkobuněčným B-lymfomem: 15letá prospektivní registrační studie na dvou kohortách
This will be a multicenter, national, non-interventional, prospective cohort study
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
Eligible participants will be pediatric (<18 years) and adult patients (aged 18 years or older) with B-cell malignancies who have received tisagenlecleucel through the commercial setting or out-of-specification (OOS) use in Brazil. We will collect data prospectively and complement missing information with retrospective data collection, when necessary. It is anticipated that approximately 200 patients will be enrolled in the cohort over 5 years divided among the study indications.
Since this is a non-interventional study, no administration of study drug or application of questionnaires will be mandated by this protocol. The study will consist of a "Pre-infusion" and a "Post infusion follow-up period" for up to 15 years post tisagenlecleucel infusion. All patients will be followed until death or last scheduled visit, whichever comes first.
For the study, "pre-infusion" and "follow-up post infusion" phases are defined as:
- "Pre-infusion" will consist of the patient's information from the time of diagnosis untiljust prior to infusion with tisagenlecleucel.
- "Follow-up Post infusion" information will comprise any information from the infusionof tisagenlecleucel onwards.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Novartis Pharmaceuticals
- Telefonní číslo: +41613241111
- E-mail: novartis.email@novartis.com
Studijní záloha kontaktů
- Jméno: Novartis Pharmaceuticals
Studijní místa
-
-
-
São Paulo, Brazílie, 01509-010
- Nábor
- Novartis Investigative Site
-
São Paulo, Brazílie, 01409-902
- Nábor
- Novartis Investigative Site
-
-
Belo Horizonte
-
Minas Gerais, Belo Horizonte, Brazílie, 34006-059
- Nábor
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazílie, 41253-190
- Nábor
- Novartis Investigative Site
-
-
Paraná
-
Curitiba, Paraná, Brazílie, 81520-060
- Nábor
- Novartis Investigative Site
-
-
São Paulo
-
São Paulo, São Paulo, Brazílie, 01323-900
- Nábor
- Novartis Investigative Site
-
São Paulo, São Paulo, Brazílie, 04544-000
- Nábor
- Novartis Investigative Site
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
The study population will include pediatric/ adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia aged 0-25 years and adult patients aged ≥ 18 years with relapsed/refractory Diffuse Large B-cell Lymphoma and relapsed/refractory follicular lymphoma, who received tisagenlecleucel infusion in the commercial setting or out-of-specification.
Popis
Inclusion Criteria:
Patients eligible for inclusion in this study must meet the following criteria:
-
Patients who receive tisagenlecleucel infusion in the commercial setting or out-of-specification (OOS) use, AND
-
Signed informed consent must be obtained prior to participation in study, AND
For ALL participants:
-
Patients of any gender aged 0-17 years (named as pediatric) with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR
-
Patients of any gender, aged 18-25 years (named as adults) - with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR
For DBLCL and FL participants:
-
Patients of any gender aged 18 years or older, who have been diagnosed with relapsed/ refractory Diffuse Large B-cell Lymphoma and received tisagenlecleucel infusion.
Exclusion Criteria:
- Patients who did not consent to data collection.
- Patients who received tisagenlecleucel infusion as part of any interventional clinical trial.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: OTHER
Počet skupin / kohort
Kohorty a intervence
Skupina / kohortaSkupina / kohorta |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Acute Lymphoblastic Leukemia (ALL)
Children/young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia who received tisagenlecleucel infusion |
Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study |
|
Diffuse Large B-cell Lymphoma (DLBCL)
Adult patients with relapsed/refractory Diffuse Large B-cell Lymphoma who received tisagenlecleucel infusion |
Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study |
|
Follicular Lymphoma (FL)
Patients of any gender aged 18 year or older, with relapsed/refractory Follicular Lymphoma who received tisagenlecleucel infusion. |
Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Overall response rate (ORR)
Časové okno: Up to 15 years
|
The overall response rate will be defined as the total proportion of participants exhibiting either the best overall response (BOR) of complete or partial responses and the proportion of patient with BOR of CR/PR or CR/CRi for ALL patients will be reported along with its 95% CI. For ALL participants, the BOR will be defined as a CR or a CRi in accordance with National Comprehensive Cancer Network (NCCN) guidelines and previous guidelines (Appelbaum et al 2007)(Cheson et al 2003). For lymphomas, the BOR will be defined as a CR or PR in accordance with the Cheson response criteria (Cheson et al 2007) and the Lugano classification (Cheson et al 2016). |
Up to 15 years
|
|
MRD negative overall response rate
Časové okno: Up to 15 years
|
The percentage of B-cell ALL patients who achieve a Best Overall Response (BOR) of CR or CRi with a Minimal residual disease (MRD) negative bone marrow will be provided with 95% CI. |
Up to 15 years
|
|
Duration of overall response (DOR)
Časové okno: Up to 15 years
|
Duration of overall response (DOR) applies only to patients whose best overall disease response was either:
DOR will be defined as the time from the date of first documented disease response (Complete Response (CR) or PR for patients with lymphomas, and Complete Remission (CR) or CRi for patients with ALL), whichever occurs first, to the date of first documented progression or first documented relapse according to indication, or to the date of death due to the underlying disease. In case a patient does not have progression/relapse or death due to underlying disease (defined as the event for this outcome) prior to data cut-off, DOR will be censored at the date of the last assessment on or prior to the earliest censoring event. |
Up to 15 years
|
|
Relapse-free survival (RFS)
Časové okno: Up to 15 years
|
RFS is measured by the time from date of first documented disease response as CR or CRi to relapse or death due to any cause in ALL patients. In case a patient does not have relapse or death due to any cause prior to data cutoff, RFS will be censored at the date of the last adequate assessment on or prior to the earliest censoring event. |
Up to 15 years
|
|
Event-free survival (EFS) for ALL patients
Časové okno: Up to 15 years
|
EFS is the time from date of first tisagenlecleucel infusion to treatment failure, relapse or death from any cause, whichever occurred first, for B-cell ALL patients. |
Up to 15 years
|
|
Progression free survival (PFS) for DLBCL patients
Časové okno: Up to 15 years
|
PFS is defined as the time from the date of first infusion to the date of event defined as the first documented progression of lymphoma or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of the last adequate assessment. In case a patient does not have progression or death prior to data cutoff, PFS will be censored at the date of the last adequate assessment on or prior to the earliest censoring event. |
Up to 15 years
|
|
Overall survival (OS)
Časové okno: Up to 15 years
|
Overall survival is the time from date of first tisagenlecleucel infusion to the date of death due to any reason, In case a patient is alive at the date of last contact on or before data cutoff, OS is censored at the date of last contact. |
Up to 15 years
|
|
Number of ALL patients with hematologic recovery
Časové okno: Up to 15 years
|
Dates of hematological recovery (i.e., dates of Absolute Neutrophil Count (ANC) and platelet recovery) will be collected. ANC recovery is defined as an ANC of ≥ 0.5 × 109/L (500/mm^3) for 3 consecutive laboratory values obtained on different days. Date of ANC recovery is the date of the first of 3 consecutive laboratory values where the ANC is ≥ 0.5 × 109/L (CIBMTR). The first date of the 3 consecutive laboratory values obtained on different days where the platelet count was ≥ 20 × 109/L should be recorded. It should be ensured that no platelet transfusions were administered for 7 days immediately preceding this date (CIBMTR). |
Up to 15 years
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The type and frequency of SAEs and AE of special interest
Časové okno: Up to 15 years
|
The type and frequency of SAEs and AE of special interest (including secondary malignancies) will be collected |
Up to 15 years
|
|
Incidence and severity of CRS and ICANS among HTLV 1 and 2 positive versus HTLV 1 and 2 negative patients
Časové okno: Up to 15 years
|
Incidence and severity of Cytokine release syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) among Human T-cell Lymphotropic Virus (HTLV) 1 and 2 positive versus HTLV 1 and 2 negative patients. For CRS AE the protocol will follow the American Society of Transplant and Cellular Therapy (ASTCT) CRS Consensus Grading. For ICANS AE the protocol will follow ASTCT consensus as well. Which establishes the Immune effector Cell-associated Encephalopathy (ICE Score) for adults/ adolescents and Cornell Assessment of Pediatric Delirium (CAPD) for pediatric patients under 12 years |
Up to 15 years
|
|
Pregnancy rates
Časové okno: Up to 15 years
|
Pregnancy rates will be collected |
Up to 15 years
|
|
Number of patients with confirmed secondary malignancies diagnosis
Časové okno: Up to 15 years
|
Number of patients with confirmed secondary malignancies diagnosis will be collected |
Up to 15 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Novotvary
- Onemocnění imunitního systému
- Novotvary podle histologického typu
- Hematologická onemocnění
- Lymfatická onemocnění
- Lymfoproliferativní poruchy
- Imunoproliferativní poruchy
- Lymfom, Non-Hodgkin
- Lymfom, B-buňka
- Lymfom
- Leukémie, lymfoidní
- Leukémie
- Hemická a lymfatická onemocnění
- Lymfom, velký B-buňka, difuzní
- Lymfoblastická leukémie-lymfom prekurzorových buněk
- Lymfom, folikulární
- Tisagenlecleucel
Další identifikační čísla studie
Další identifikační čísla studie
- CCTL019BBR02
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .